<DOC>
	<DOCNO>NCT01002248</DOCNO>
	<brief_summary>This randomized Phase III study evaluate efficacy safety perifosine add combination bortezomib dexamethasone multiple myeloma patient relapse prior bortezomib treatment regimen .</brief_summary>
	<brief_title>Assessment Efficacy Safety Perifosine , Bortezomib Dexamethasone Multiple Myeloma Patients</brief_title>
	<detailed_description>A pre-planned interim analysis expect take place Q1 2013 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient previously diagnose multiple myeloma base standard diagnostic criterion . Patients must relapse ( progress &gt; 60 day ) last dose bortezomibbased therapy . In addition , patient may relapse refractory nonbortezomibbased therapy . Patient receive least 1 4 prior antimyeloma regimen progressive disease recent treatment regimen . Patients must adequate organ marrow function . Patients must refractory bortezomibcontaining regimen . History allergic reaction intolerance attribute compound similar chemical biologic composition perifosine ( miltefosine edelfosine ) , bortezomib dexamethasone component . Prior treatment perifosine investigational proteasome inhibitor . Chemotherapy therapy experimental proven may active myeloma within two week ( 14 day ) prior Cycle 1 Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed multiple myeloma</keyword>
	<keyword>Refractory multiple myeloma</keyword>
	<keyword>Relapsed refractory multiple myeloma</keyword>
</DOC>